{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:33:36Z","timestamp":1793424816239,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008738","name":"Jeanssons Stiftelser","doi-asserted-by":"publisher","award":["J2021-0041"],"award-info":[{"award-number":["J2021-0041"]}],"id":[{"id":"10.13039\/100008738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010769","name":"Petrus och Augusta Hedlunds Stiftelse","doi-asserted-by":"publisher","award":["M-2021-1743"],"award-info":[{"award-number":["M-2021-1743"]}],"id":[{"id":"10.13039\/100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007435","name":"\u00c5ke Wiberg Stiftelse","doi-asserted-by":"publisher","award":["M22-0040"],"award-info":[{"award-number":["M22-0040"]}],"id":[{"id":"10.13039\/100007435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00799"],"award-info":[{"award-number":["2022-00799"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuroinflammation is a significant contributor to the pathology of glaucoma. Targeting key-mediators in this process is a realistic option to slow disease progression. Galectin-3 is a \u03b2-galactoside binding lectin that has been associated with inflammation in both systemic and central nervous system diseases. Elevated Galectin-3 has recently been detected in multiple animal models of glaucoma and inhibiting Galectin-3 using an intravitreal injection of TD139 (a Galectin-3 small molecule inhibitor) is neuroprotective. We queried whether this neuroprotective effect was translatable to another animal model and species. TD139 was intravitreally injected,\u00a0in a rat ocular hypertensive model of glaucoma, 3 days after the induction of ocular hypertension (at peak intraocular pressure).\u00a0Retinal ganglion cell survival and glial morphological markers were quantified. The degeneration of retinal ganglion cells was prevented by TD139 injection, but gross glial markers remained unaffected. These data confirm that the intravitreal injection of TD139 is neuroprotective in a rat ocular hypertensive model of glaucoma, while suggesting that the inhibition of Galectin-3 is not sufficient to alter the gross inflammatory outcome.<\/jats:p>","DOI":"10.1186\/s13041-024-01160-z","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:51:17Z","timestamp":1732247477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Anne","family":"Rombaut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Brautaset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-8397","authenticated-orcid":false,"given":"Pete A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-7358","authenticated-orcid":false,"given":"James R.","family":"Tribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"crossref","unstructured":"Giri PM, Banerjee A, Ghosal A, Layek B. Neuroinflammation in neurodegenerative disorders: current knowledge and therapeutic implications. Int J Mol Sci. 2024;25(7).","DOI":"10.3390\/ijms25073995"},{"issue":"5","key":"1160_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.survophthal.2021.02.003","volume":"66","author":"L Quaranta","year":"2021","unstructured":"Quaranta L, Bruttini C, Micheletti E, Konstas AGP, Michelessi M, Oddone F, et al. Glaucoma and neuroinflammation: an overview. Surv Ophthalmol. 2021;66(5):693\u2013713.","journal-title":"Surv Ophthalmol"},{"key":"1160_CR3","doi-asserted-by":"crossref","unstructured":"Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M et al. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules. 2020;10(3).","DOI":"10.3390\/biom10030389"},{"issue":"9","key":"1160_CR4","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4103\/1673-5374.391181","volume":"19","author":"BM Lozinski","year":"2024","unstructured":"Lozinski BM, Ta K, Dong Y. Emerging role of galectin 3 in neuroinflammation and neurodegeneration. Neural Regen Res. 2024;19(9):2004\u20139.","journal-title":"Neural Regen Res"},{"issue":"11","key":"1160_CR5","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.2174\/1570159X20666220201094547","volume":"20","author":"MM Ge","year":"2022","unstructured":"Ge MM, Chen N, Zhou YQ, Yang H, Tian YK, Ye DW. Galectin-3 in microglia-mediated neuroinflammation: implications for Central Nervous System diseases. Curr Neuropharmacol. 2022;20(11):2066\u201380.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"1160_CR6","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.4049\/jimmunol.165.4.2156","volume":"165","author":"H Sano","year":"2000","unstructured":"Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol. 2000;165(4):2156\u201364.","journal-title":"J Immunol"},{"issue":"7","key":"1160_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/glia.20962","volume":"58","author":"JL Son","year":"2010","unstructured":"Son JL, Soto I, Oglesby E, Lopez-Roca T, Pease ME, Quigley HA, et al. Glaucomatous optic nerve injury involves early astrocyte reactivity and late oligodendrocyte loss. Glia. 2010;58(7):780\u20139.","journal-title":"Glia"},{"issue":"3","key":"1160_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1073\/pnas.1013965108","volume":"108","author":"JV Nguyen","year":"2011","unstructured":"Nguyen JV, Soto I, Kim KY, Bushong EA, Oglesby E, Valiente-Soriano FJ, et al. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci U S A. 2011;108(3):1176\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1160_CR9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.immuni.2022.07.014","volume":"55","author":"MA Margeta","year":"2022","unstructured":"Margeta MA, Yin Z, Madore C, Pitts KM, Letcher SM, Tang J, et al. Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. Immunity. 2022;55(9):1627\u2013e447.","journal-title":"Immunity"},{"issue":"1","key":"1160_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.10.1.22","volume":"10","author":"JR Tribble","year":"2021","unstructured":"Tribble JR, Kokkali E, Otmani A, Plastino F, Lardner E, Vohra R, et al. When is a control not a control? Reactive microglia occur throughout the Control Contralateral pathway of retinal ganglion cell projections in experimental Glaucoma. Transl Vis Sci Technol. 2021;10(1):22.","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"1160_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.10.1.21","volume":"10","author":"JR Tribble","year":"2021","unstructured":"Tribble JR, Otmani A, Kokkali E, Lardner E, Morgan JE, Williams PA. Retinal ganglion cell degeneration in a rat magnetic bead model of ocular hypertensive Glaucoma. Transl Vis Sci Technol. 2021;10(1):21.","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"1160_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13024-018-0303-3","volume":"14","author":"PA Williams","year":"2019","unstructured":"Williams PA, Braine CE, Kizhatil K, Foxworth NE, Tolman NG, Harder JM, et al. Inhibition of monocyte-like cell extravasation protects from neurodegeneration in DBA\/2J glaucoma. Mol Neurodegener. 2019;14(1):6.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1160_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1021\/acs.jmedchem.9b01692","volume":"63","author":"K Bratteby","year":"2020","unstructured":"Bratteby K, Torkelsson E, L\u2019Estrade ET, Peterson K, Shalgunov V, Xiong M, et al. In vivo veritas: 18F-Radiolabeled glycomimetics allow insights into the pharmacological fate of Galectin-3 inhibitors. J Med Chem. 2020;63(2):747\u201355.","journal-title":"J Med Chem"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-024-01160-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-024-01160-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-024-01160-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T08:02:11Z","timestamp":1732262531000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-024-01160-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1186\/s13041-024-01160-z","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were undertaken following the Association for Research for Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Research. Individual study protocols were approved by Stockholm\u2019s Committee for Ethical Animal Research (10389\u2009\u2212\u20092018, 14053\u2009\u2212\u20092020, 3909\u2009\u2212\u20092023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}